查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046266

遺傳性血管性水腫治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類別、分銷管道、應用、地區和競爭格局分類，2021-2031年

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球遺傳性血管性水腫 (HAE) 治療市場預計將從 2025 年的 44.1 億美元大幅成長至 2031 年的 73.6 億美元，複合年成長率為 8.91%。

這些特效藥物旨在治療C1抑制劑缺乏症，不僅包括用於治療突發性急性發作的藥物，還包括用於預防性治療以減少腫脹發生頻率的藥物。推動該市場發展的關鍵因素包括：越來越多的患者被發現先前未被診斷，以及對口服預防性藥物的需求不斷成長，因為口服藥物比注射劑更方便。此外，已開發國家完善的保險報銷政策也持續改善了患者獲得這些重要生物製藥和小分子藥物的機會。

市場概覽
預測期 2027-2031
市場規模：2025年 44.1億美元
市場規模：2031年 73.6億美元
複合年成長率：2026-2031年 8.91%
成長最快的細分市場 預防
最大的市場 北美洲

儘管市場成長預期良好，但仍面臨許多挑戰。尤其突出的是診斷嚴重滯後，導致相當一部分患者長期未治療。誤診也是一大障礙。由於遺傳性血管性水腫 (HAE) 的症狀很容易與常見的過敏反應混淆，現有治療方法未能有效利用。 HAE International 在 2024 年的報告中指出，作為衡量目前治療可近性的指標，其 78% 的成員機構將至少獲得一種遺傳性血管性水腫的治療方案。這表明，儘管治療方案的可及性正在改善，但治療機會不均仍然是充分發揮市場潛力的一大障礙。

市場促進因素

推動市場發展的關鍵因素之一是治療模式從按需治療向長期預防性治療的根本性轉變，這主要得益於便捷的口服給藥方式的日益普及。患者和醫生都越來越傾向於預防性治療，與傳統的注射式急性治療相比，預防性治療能有效降低發作頻率，減輕用藥負擔，從而顯著提高患者的生活品質。這種策略轉變在商業性也顯而易見，正迅速改變該領域的收入來源。 2024年11月，BioCryst Pharmaceuticals公司報告稱，其ORLADEYO產品2024年第三季淨銷售額達到1.163億美元，年成長35.7%，顯示與傳統治療方法相比，患者對口服預防性治療的需求強勁。

同時，市場正受到強勁的臨床研發管線的推動，其中包括正在開發的下一代生物製藥和基因療法，旨在提供持久療效並最終實現治癒。諸如基於體內CRISPR的基因編輯等創新技術正在臨床試驗中取得進展，展現出令人鼓舞的療效，有望重新定義標準治療的概念，並有可能消除長期用藥的必要性。例如，Interior Therapeutics公司在2024年10月報告稱，在其二期臨床試驗的第5至16週期間，單次50毫克劑量的NTLA-2002與安慰劑相比，平均每月癲癇發作率降低了81%。商業領域也保持著強勁的勢頭。 Pharming Group NV報告稱，2024年第三季總銷售額成長12%，達到7,480萬美元，這反映了全球治療領域持續的經濟成長動能。

市場挑戰

全球遺傳性血管性水腫 (HAE) 治療市場成長的最大障礙仍然是診斷延遲和誤診普遍存在這一根深蒂固的問題。由於 HAE 的症狀與常見的組織胺過敏反應非常相似，第一線醫護人員往往無法準確識別疾病，經常開立無效的抗組織胺或皮質類固醇，而不是所需的標靶治療。治療早期階段的這種混淆嚴重限制了潛在患者轉化為 HAE 治療實際使用者。因此，製藥公司面臨著一個巨大的障礙：由於許多患者無法獲得或購買這些特殊的生物製藥和小分子藥物，僅僅因為他們的病情沒有得到正確診斷，導致其目標市場被人為地抑制。

近期數據顯示，大量患者未被醫療系統識別和忽視，進一步凸顯了診斷缺口的嚴重性。據HAE International預測，到2024年，該疾病的診斷率僅53%。這意味著近一半的潛在患者群仍未被確診，因此也無法接受治療性介入。除非這些重大的診斷瓶頸得到有效解決，否則市場規模將繼續遠低於其潛在收入水準。因此，相當一部分需要改變人生的預防和急性照護的人群的需求將無法得到滿足。

市場趨勢

RNA標靶治療方法的商業化代表著預防醫學領域的重大變革，標誌著治療策略從蛋白質替代療法轉向上游抑制前激肽釋放酶的合成。與傳統的C1酯酶抑制劑不同，這些反義寡核苷酸透過定序疾病路徑中涉及的特定mRNA發揮作用，為對標準治療無反應或需要縮短給藥間隔的患者提供了一種新的治療機制。這類療法已顯著降低了癲癇發作頻率，從而展現了RNA干擾重塑標準治療方案的潛力。 2024年5月，Ionis Pharmaceuticals公司公佈了3期OASIS-HAE治療方法的結果，強調了這種新療法的顯著療效。在該試驗中，接受在臨床實驗RNA標靶治療donidalorsen治療的患者，其平均每月癲癇發作頻率較安慰劑組降低了87%。

同時，儘管口服替代藥物數量不斷增加，但半衰期延長的生物製藥的研發仍在持續佔據顯著的市場佔有率，並保持其重要性。口服療法雖然方便，但針對血漿激肽釋放酶的單株抗體能夠為那些優先考慮最大限度預防癲癇發作而非給藥途徑的患者提供持續且高效的控制。該領域正透過減少皮下注射頻率的製劑不斷拓展，確保即使在最嚴重的病例中也能實現長期依從性和穩定性。此類藥物的經濟韌性極高。 2024年10月，武田藥品工業株式會社報告稱，其皮下預防性治療藥物Tachyjilo在2024會計年度上半年的銷售額達到953億日元，這表明即使在競爭日益激烈的市場環境中，市場對成熟的注射用生物製劑的需求依然強勁。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：遺傳性血管性水腫治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（C1酯酶抑制劑、選擇性緩激肽B2受體拮抗劑、激肽釋放酶抑制劑及其他藥物類別）
    • 分銷管道（醫院藥房、零售藥房、其他分銷管道）
    • 透過應用（預防、按需）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美遺傳性血管性水腫治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲遺傳性血管性水腫治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區遺傳性血管性水腫治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲遺傳性血管性水腫治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲遺傳性血管性水腫治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球遺傳性血管性水腫治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Takeda Pharmaceutical Company Limited
  • CSL Behring LLC
  • BioCryst Pharmaceuticals, Inc.
  • Pharming Group NV
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Intellia Therapeutics, Inc.
  • Astria Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17501

The global Hereditary Angioedema (HAE) therapeutics market is projected to expand significantly, increasing from USD 4.41 billion in 2025 to USD 7.36 billion by 2031, demonstrating an 8.91% compound annual growth rate. These specialized pharmaceutical interventions are designed to address C1-inhibitor deficiency and include acute treatments for sudden attacks as well as prophylactic agents to lessen the frequency of swelling. Key drivers for this market include the enhanced identification of previously undiagnosed individuals and a growing preference for convenient oral preventative treatments over injectable options. Furthermore, supportive reimbursement policies in developed economies continue to improve patient access to these vital biologic and small-molecule medications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.41 Billion
Market Size 2031USD 7.36 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentProphylaxis
Largest MarketNorth America

Despite this projected growth, the market contends with considerable challenges, particularly extensive diagnostic delays that often result in prolonged periods of untreated HAE for a significant portion of the patient population. Misdiagnosis presents a critical obstacle, as HAE symptoms are frequently mistaken for common allergic reactions, thereby restricting the effective utilization of available therapies. As an indicator of current accessibility, HAE International reported in 2024 that 78% of its member organizations had access to at least one hereditary angioedema medication. This highlights that while therapeutic availability is improving, inconsistent access remains a barrier to realizing the market's full potential.

Market Driver

A primary market driver is the fundamental shift from on-demand treatment to long-term prophylaxis, significantly supported by the increasing adoption of patient-friendly oral administration methods. Both patients and physicians are increasingly favoring preventative regimens that effectively reduce attack frequency and ease the burden of administration compared to traditional injectable acute therapies, thereby markedly enhancing the quality of life. This strategic transition is commercially evident, rapidly transforming revenue streams within the sector. BioCryst Pharmaceuticals reported in November 2024 that ORLADEYO's net revenue reached $116.3 million in the third quarter of 2024, marking a 35.7% year-over-year increase and underscoring robust patient demand for oral prophylactic options over older treatments.

Concurrently, the market is propelled by a robust clinical pipeline featuring next-generation biologics and gene therapies, which are being developed to offer durable and potentially curative outcomes. Innovations such as in vivo CRISPR-based editing are progressing through clinical stages with promising efficacy profiles, poised to redefine standard care by potentially eliminating the need for chronic dosing. Illustrating this advancement, Intellia Therapeutics noted in October 2024 that a single 50 mg dose of NTLA-2002 resulted in an 81% mean monthly attack rate reduction compared to placebo during weeks 5 through 16 of its Phase 2 study. The commercial sector also remains dynamic; Pharming Group N.V. reported in 2024 a 12% increase in total third-quarter revenues to US$74.8 million, reflecting sustained economic momentum across the global therapeutic landscape.

Market Challenge

The foremost impediment to the growth of the Global Hereditary Angioedema Therapeutics Market remains the persistent issue of diagnostic delays and widespread misdiagnosis. Since HAE symptoms closely resemble common histaminergic allergic reactions, frontline healthcare providers often fail to accurately identify the condition, frequently prescribing ineffective antihistamines or corticosteroids instead of the necessary targeted therapies. This confusion at the initial point of care severely limits the conversion of the potential patient population into active consumers of HAE therapeutics. Consequently, pharmaceutical companies face a significant barrier where the addressable market is artificially suppressed, as a large number of patients cannot access or purchase these specialized biologic and small-molecule drugs simply because their condition has not been correctly identified.

The sheer scale of this diagnostic gap is further emphasized by recent data, which highlights how many patients remain unrecognized by the healthcare system. According to HAE International, the diagnosis rate for the condition was reported to be merely 53% in 2024. This statistic indicates that almost half of the potential patient base remains undiagnosed and, consequently, unreachable for therapeutic intervention. Until these critical diagnostic bottlenecks are effectively resolved, the market will continue to operate substantially below its full revenue potential, unable to fully capitalize on the demand from a significant segment of the population requiring these life-altering prophylactic and acute treatments.

Market Trends

The commercialization of RNA-targeted therapies signifies a precise evolution in prophylactic care, moving beyond protein replacement to upstream inhibition of prekallikrein synthesis. Unlike conventional C1-esterase inhibitors, these antisense oligonucleotides function by silencing the specific mRNA responsible for the disease pathway, offering a novel mechanism for patients who are unresponsive to standard treatments or those seeking less frequent dosing intervals. This therapeutic class effectively achieves a significant reduction in attack frequency, thereby validating the potential of RNA interference to redefine standard management protocols. Ionis Pharmaceuticals reported in May 2024 from the Phase 3 OASIS-HAE Study that patients treated with the investigational RNA-targeted medicine, donidalorsen, experienced an 87% reduction in mean monthly attack rates compared to placebo, underscoring the robust efficacy of this emerging modality.

Simultaneously, the development of extended half-life biologics continues to capture significant market share, maintaining its relevance despite the increasing availability of oral alternatives. While oral regimens offer convenience, monoclonal antibodies that target plasma kallikrein provide sustained, high-efficacy control for patients who prioritize maximum attack prevention over the administration route. This segment is expanding through formulations that enable less frequent subcutaneous dosing, ensuring long-term adherence and stability for the most severe cases. The economic resilience of this category is substantial; Takeda Pharmaceutical Company Limited reported in October 2024 that revenue for its subcutaneous prophylactic treatment, Takhzyro, grew to 95.3 billion JPY in the first half of fiscal year 2024, demonstrating persistent demand for established injectable biologics amid a diversifying competitive landscape.

Key Market Players

  • Takeda Pharmaceutical Company Limited
  • CSL Behring LLC
  • BioCryst Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Intellia Therapeutics, Inc.
  • Astria Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG

Report Scope

In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hereditary Angioedema Therapeutics Market, By Drug Class

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Other Drug Classes

Hereditary Angioedema Therapeutics Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

Hereditary Angioedema Therapeutics Market, By Application

  • Prophylaxis
  • On-demand

Hereditary Angioedema Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.

Available Customizations:

Global Hereditary Angioedema Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hereditary Angioedema Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
    • 5.2.3. By Application (Prophylaxis, On-demand)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Hereditary Angioedema Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel
        • 6.3.3.2.3. By Application

7. Europe Hereditary Angioedema Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
        • 7.3.1.2.3. By Application
    • 7.3.2. France Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel
        • 7.3.5.2.3. By Application

8. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
        • 8.3.1.2.3. By Application
    • 8.3.2. India Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel
        • 8.3.5.2.3. By Application

9. Middle East & Africa Hereditary Angioedema Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Hereditary Angioedema Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Hereditary Angioedema Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel
        • 9.3.3.2.3. By Application

10. South America Hereditary Angioedema Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Hereditary Angioedema Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Hereditary Angioedema Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Takeda Pharmaceutical Company Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. CSL Behring LLC
  • 15.3. BioCryst Pharmaceuticals, Inc.
  • 15.4. Pharming Group N.V.
  • 15.5. Ionis Pharmaceuticals, Inc.
  • 15.6. KalVista Pharmaceuticals, Inc.
  • 15.7. Intellia Therapeutics, Inc.
  • 15.8. Astria Therapeutics, Inc.
  • 15.9. Alnylam Pharmaceuticals, Inc.
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer